- •Persistent NAFLD showed increased risk of myocardial infarction, stroke, heart failure, and mortality compared with non-NAFLD.
- •Regression NAFLD was associated with decreased risk HF and mortality compared with persistent NAFLD.
- •Persistent hepatic fibrosis was associated with increased risk of stroke, heart failure and mortality compared with non-fibrosis.
- •Compared with persistent hepatic fibrosis, regression of hepatic fibrosis demonstrated decreased risk of MI, stroke, HF, and mortality.
- •Changes in hepatic steatosis and fibrosis based on FLI or BARD score could identify higher risk group for CVD and mortality among new-onset T2DM.
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) have a synergistic effect on cardiovascular disease (CVD). We investigated the association of changes in hepatic steatosis and advanced hepatic fibrosis with risk of CVD and mortality in new-onset T2DM.
Using the Korean National Health Insurance dataset, we included 120,256 patients with new-onset T2DM. Hepatic steatosis and advanced hepatic fibrosis were determined using the fatty liver index (FLI) and BARD score. According to the changes of the two scores over two years, patients were divided into four groups and analyzed for development of myocardial infarction (MI), stroke, heart failure (HF), and mortality.
Incident hepatic steatosis was associated with increased development of stroke, HF, and mortality compared with non-NAFLD (all p < 0.05). Regression and persistent hepatic steatosis were associated with increased risk of MI, stroke, HF, and mortality compared with non-NAFLD (all p < 0.05). Persistent advanced hepatic fibrosis was associated with increased risk of stroke, HF, and mortality (all p < 0.05).) Compared with persistent hepatic fibrosis, regression of hepatic fibrosis was associated with decreased risk of stroke, HF, and mortality (all p < 0.05).
Changes in FLI or BARD score were associated with CVD and mortality in new-onset T2DM.
Abbreviations:BMI (body mass index), CI (confidence interval), CVD (cardiovascular disease), FLI (fatty liver index), HF (heart failure), HR (hazard ratio), MI (myocardial infarction), NAFLD (Nonalcoholic fatty liver disease)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications.J Hepatol. 2016; 65: 425-443https://doi.org/10.1016/j.jhep.2016.04.005
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.Gut. 2017; 66: 1138-1153https://doi.org/10.1136/gutjnl-2017-313884
- Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.Gastroenterology. 1999; 116: 1413-1419https://doi.org/10.1016/s0016-5085(99)70506-8
- Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatology. 2006; 44: 865-873
- NAFLD: a multisystem disease.J Hepatol. 2015; 62: S47-S64https://doi.org/10.1016/j.jhep.2014.12.012
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology. 2015; 61: 1547-1554
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology. 2016; 64: 73-84https://doi.org/10.1002/hep.28431
- Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up.J Hepatol. 2012; 56: 1145-1151
- Incidence and natural course of fatty liver in the general population: the Dionysos study.Hepatology. 2007; 46: 1387-1391
- Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up.Sci Rep. 2018; 8https://doi.org/10.1038/s41598-018-25641-z
- The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.Ann Intern Med. 2005; 143: 722https://doi.org/10.7326/0003-4819-143-10-200511150-00009
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol. 2015; 13: 643-654
- Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes.Diabetes Care. 2015; 38: 1673-1679https://doi.org/10.2337/dc15-0140
- Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins.Atherosclerosis. 2018; 272: 47-53
- The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol. 2006; 6: 33https://doi.org/10.1186/1471-230x-6-33
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut. 2008; 57: 1441-1447https://doi.org/10.1136/gut.2007.146019
- The association of hepatic steatosis and fibrosis with heart failure and mortality.Cardiovasc Diabetol. 2021; 20https://doi.org/10.1186/s12933-021-01374-8
- The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study.Cardiovasc Diabetol. 2022; 21https://doi.org/10.1186/s12933-022-01483-y
- Background and data configuration process of a nationwide population-based study using the korean national health insurance system.Diabetes Metab J. 2014; 38: 395https://doi.org/10.4093/dmj.2014.38.5.395
- Early mortality and cardiovascular disease, varied association with body mass index and its changes in insulin-treated diabetes: a nationwide study.Int J Obes (Lond). 2021; 45: 2482-2489
- Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms.Alcohol Alcohol. 2002; 37: 409-415https://doi.org/10.1093/alcalc/37.5.409
- Association between alcohol consumption pattern and the incidence risk of type 2 diabetes in Korean men: A 12-years follow-up study.Sci Rep. 2017; 7: 7322https://doi.org/10.1038/s41598-017-07549-2
- Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study.Eur Heart J. 2017; 38: 3560-3566
- The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases.Hepatology. 2018; 67: 328-357
- Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.Mayo Clin Proc. 2015; 90: 1233-1246https://doi.org/10.1016/j.mayocp.2015.06.013
- Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.World J Gastroenterol. 2013; 19: 57-64https://doi.org/10.3748/wjg.v19.i1.57
- Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study.Hepatol Res. 2016; 46: 862-870
- Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers.J Hepatol. 2018; 68: 305-315https://doi.org/10.1016/j.jhep.2017.11.013
- Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: a position statement of the fatty liver research group of the korean diabetes association.Diabetes Metab J. 2020; 44: 382https://doi.org/10.4093/dmj.2020.0010
- Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review.Front Med (Lausanne). 2019; 6: 202https://doi.org/10.3389/fmed.2019.00202
- Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: a Call to Action.Diabetes Care. 2017; 40: 419-430https://doi.org/10.2337/dc16-1787
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.Hepatology. 2010; 51: 121-129
- Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology. 2015; 149: 367-378
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med. 2006; 355: 2297-2307
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.Hepatology. 2004; 39: 188-196
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: a Meta-analysis.JAMA Intern Med. 2017; 177: 633-640https://doi.org/10.1001/jamainternmed.2016.9607
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.N Engl J Med. 2021; 384: 1113-1124
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: a Randomized, Double-Blind.Placebo-Controlled Trial Adv Ther. 2020; 37: 4697-4708
Published online: November 26, 2022
Accepted: November 23, 2022
Received in revised form: November 17, 2022
Received: October 22, 2022
© 2022 Elsevier B.V. All rights reserved.